American journal of cancer research最新文献

{"title":"Potential therapeutic targets for bladder cancer: a proteome-wide Mendelian randomization study.","authors":"Jia-Hao Liu, Yuan-Zhuo Du, Fang Liu, Lin Yang, Xiao-Qiang Liu, Bin Fu, Xiao-Rong Yang","doi":"10.62347/UBEJ3345","DOIUrl":"https://doi.org/10.62347/UBEJ3345","url":null,"abstract":"<p><p>The incidence of bladder cancer (BCa) is increasing worldwide and the development of drug targets for BCa is necessary. We conducted a proteome-wide association study (PWAS) mainly using mendelian randomization (MR) to explore the causal proteins associated with BCa. Protein quantitative trait locis (pQTLs) were derived from two large proteome genome-wide association studies. After validation by multiple sensitivity analysis and two replication analyses, we identified five plasma proteins showed significant causal associations with BCa. Our study indicated that GSTM4 (OR = 0.81 (0.74-0.89), <i>P</i> = 5.14 × 10^-6, PPH4 = 0.89) emerged as the most reliable target. Besides, PSCA, LY6D, SLURP1 and GSTM1 also showed clear causal association but only failed in colocalization. We also performed several downstream analyses. Protein-protein interactions analysis found these causal targets came from glutathione S-transferase family or lymphocyte antigen-6 family. Phenome-wide MR analysis revealed PSCA may lead to peptic ulcer and local infections of skin and subcutaneous tissue. We then employed single-cell analysis, protein-protein interactions, and druggability evaluation. Phenome-wide MR analysis was to assess the possible side effects of these drug targets. Finally, the reliability of GSTM4 in BCa was confirmed via colony formation assay.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1096-1108"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prediction of lymph node metastasis in cervical cancer patients using AdaBoost machine learning model: analysis of risk factors.","authors":"Nan Li, Erxuan Peng, Fenghua Liu","doi":"10.62347/UMKG8609","DOIUrl":"https://doi.org/10.62347/UMKG8609","url":null,"abstract":"<p><p>This study focuses on the development and evaluation of machine learning models, particularly the Adaptive Boosting (AdaBoost) algorithm, for predicting lymph node metastasis (LNM) in cervical cancer (CC) patients. The findings show that AdaBoost outperformed traditional statistical methods and other machine learning models, including Random Forest, Support Vector Machine (SVM), and Least Absolute Shrinkage and Selection Operator (LASSO) regression, in predicting LNM. The areas under the curve (AUCs) for the training and validation sets were 0.882 and 0.857, respectively, indicating high prediction efficiency. Multivariate logistic regression identified key independent risk factors for LNM, including FIGO staging, squamous cell carcinoma antigen (SCC-Ag), white blood cell count (WBC), neutrophil count (NEUT), hemoglobin (HGB) level, and prealbumin (PAB) level. These factors are significant in predicting LNM and emphasize their importance in clinical decision-making. AdaBoost's ability to predict LNM preoperatively, without invasive procedures such as lymph node dissection, can reduce treatment risks and improve patient outcomes. While other models, such as XGBoost, showed a marginally higher AUC in training, AdaBoost's performance in validation was comparable (P=0.18). Inflammatory and nutritional markers, such as WBC, NEUT, HGB, and PAB, were significant predictors and provide valuable insights into tumor progression. Despite the study's retrospective nature, the integration of larger, multi-center datasets, and multi-modal imaging could further enhance the model's accuracy and generalizability. This high-performance AdaBoost model offers clinical potential for refining personalized treatment strategies for CC patients.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1158-1173"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of ultrasound assessment of axillary and brachial artery parameters for lymph node metastasis in breast cancer patients.","authors":"Jingcheng Bi, Tianqi Yao, Yu Yao, Weimin Li, Xiaofei Shen, Qiucheng Lei, Tao Li, Lianghe Jiao, Zhengcai Zhu","doi":"10.62347/EBEI7017","DOIUrl":"https://doi.org/10.62347/EBEI7017","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the predictive value of ultrasound assessment of axillary and brachial artery parameters for lymph node metastasis (LNM) in breast cancer (BRCA) patients.</p><p><strong>Methods: </strong>The clinical data of 172 cancer patients were reviewed, and the patients were stratified into two groups based on the presence or absence of axillary LNM. Ultrasound assessment was employed to evaluate axillary and brachial artery parameters using specific techniques, and arterial characteristics were analyzed.</p><p><strong>Results: </strong>Significant differences were observed in the ultrasound parameters of both axillary and brachial arteries between the non-LNM and LNM groups. Specifically, axillary and brachial artery diameters and resistive index exhibited significant differences and correlations with axillary LNM. Furthermore, molecular markers such as human epidermal growth factor receptor 2 (HER2) status, estrogen receptor (ER) status, and progesterone receptor (PR) status were found to be significantly correlated with LNM. Additionally, a nomogram was constructed, demonstrating the predictive value of the integrated arterial parameters. The combined model, incorporating axillary and brachial artery parameters, exhibited a higher predictive capability for axillary LNM compared to individual arterial parameters (AUC = 0.984).</p><p><strong>Conclusion: </strong>Ultrasound assessment of axillary and brachial artery parameters, in conjunction with molecular markers, holds promise as a non-invasive tool for predicting LNM in BRCA patients. The observed correlations provide insights into the potential clinical relevance of arterial parameters in risk stratification and treatment planning. Further research in larger, prospective cohorts is warranted to validate the findings and enhance the precision of BRCA management.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1066-1080"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982729/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune cell infiltration as a prognostic factor in endometrial cancer: a meta-analysis.","authors":"Yibin Lin, Qiaoming Lin, Qi Guan, Danru Chen, Yan Zhou, Sang Li","doi":"10.62347/BXZM8857","DOIUrl":"https://doi.org/10.62347/BXZM8857","url":null,"abstract":"<p><p>The immune system's role in cancer development and progression is receiving increasing attention. Endometrial cancer, common gynecological malignancy, has exhibited promising responses to immunotherapies. This study aims to assess the prognostic significance of various immune cell subsets in endometrial cancer, focusing on potential novel biomarkers and therapeutic targets. A systematic literature review and meta-analysis were conducted. Eleven eligible studies, comprising 2,319 patients with endometrial cancer, were included. The primary outcome was the association between levels of immune cell types, particularly CD8+ T cells, and overall prognosis. The meta-analysis found that high levels of tumor-infiltrating lymphocytes (TILs), particularly CD8+ T cells, were significantly associated with better overall prognosis in endometrial cancer patients. These findings suggest that the tumor immune microenvironment plays a crucial role in endometrial cancer prognosis. This meta-analysis indicates that higher levels of CD8+ T cells in the tumor microenvironment are linked to improved prognosis in endometrial cancer, underscoring the immune system's potential in prognostication and therapy.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1335-1345"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143959128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Itaconate targets the ERK2 signal to suppress estrogen receptor-positive breast cancer cell growth.","authors":"Hsueh-Chun Wang, Yi-Chuan Li, Mien-Chie Hung","doi":"10.62347/LHYO6433","DOIUrl":"https://doi.org/10.62347/LHYO6433","url":null,"abstract":"<p><p>Over 70% of breast cancers are estrogen receptor (ER)-positive, with Tamoxifen (Tam) being a standard treatment. However, around 40% of these cancers develop resistance to Tam, which poses a significant clinical challenge. The ACOD1/itaconate (ITA) axis, a metabolic pathway that produces itaconate, has shown promise in inhibiting the growth of ER-positive breast cancer cells. Nonetheless, it remains unclear how effective ITA is against Tam-resistant breast cancer cells and the underlying mechanisms involved. The current report found that Tam-resistant cells exhibit increased sensitivity to ITA compared to their parental cells and show a synergetic effect in combination treatment with Tam. An unbiased proteomic analysis revealed that upregulating the ERK2 signaling pathway contributes to the sensitivity of ER-positive breast cancer cells to ITA. ITA treatment increases ERK2 phosphorylation at T185/Y187 sites by directly alkylating cysteine 254, leading to ERK2 activation and subsequent cell growth inhibition. These effects were abolished in ITA allylation-resistant cells when a cysteine residue was replaced with serine. Additionally, itaconate-induced ERK2 phosphorylation and activation inhibits the growth of Tam-resistant breast cancer cells, which effect is advanced in phosphorylation-mimic ERK2_T185E-expressing cells but blocked in those expressing non-phosphorylation-mimic ERK2_T185A. Furthermore, activated ERK2 interacts physically with API5 to disrupt API5's localization to the nucleus speckle, where API5 may interact with other molecules critical in regulating cell growth-related genes. Our findings clarify the mechanism through which ITA exerts its effects on tamoxifen-sensitive and resistant breast cancer cells and highlight the potential of itaconate as an alternative treatment strategy against breast cancer.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1133-1147"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143951872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epigenetic regulation and tumor suppressive function of lncRNA EP300-AS1 in nasopharyngeal carcinoma through activation of TFAP2C binding to CST6: implications for diagnosis, prognosis, and therapy.","authors":"Chengliang Xing, Shun Ding, Tingting Duan, Zhiqun Li, Jinren Yan, Yu Kuang, Qibing Liu, Zhonglin Mu","doi":"10.62347/MCYV5235","DOIUrl":"https://doi.org/10.62347/MCYV5235","url":null,"abstract":"<p><p>The long non-coding RNA EP300-AS1 (lncRNA EP300-AS1), identified as a potential regulatory factor in various cancers, remains underexplored in nasopharyngeal carcinoma (NPC). This study investigated EP300-AS1's regulatory mechanisms in NPC, particularly its interaction with transcription factor AP-2 Gamma (TFAP2C) and its effect on cystatin E/M (CST6) expression. Employing clinical samples and NPC cell lines, we conducted in vitro and in vivo xenograft experiments to assess the impacts of modulating EP300-AS1 expression. Techniques such as CCK8, migration, scratch, apoptosis assays, cell cycle analysis, immunoblotting, and fluorescence experiments elucidated EP300-AS1's role in NPC. The interaction between EP300-AS1 and TFAP2C in regulating CST6 expression was verified using FISH, ChIP, RNA pull-down, and silver staining assays. Results indicated lower expression levels of EP300-AS1 and CST6 in NPC, with EP300-AS1 suppression inhibiting cell proliferation, migration, and invasion, while promoting apoptosis and maintaining the cell cycle in the G1 phase. EP300-AS1 also modulated epithelial-mesenchymal transition (EMT) marker expression, suggesting a role in metastasis control. Conclusively, EP300-AS1 acts as a potential tumor suppressor in NPC by interacting with TFAP2C and targeting CST6, offering novel biomarkers and therapeutic targets through its influence on methylation and the tumor microenvironment.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"894-928"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143952246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of paclitaxel combined with oxaliplatin in the treatment of advanced primary hepatocellular carcinoma.","authors":"Qian Chen, Guangyi Gao, Ying Yuan, Yan Zong, Xiaofeng Zhao, Hai Guo","doi":"10.62347/ZKIG9938","DOIUrl":"https://doi.org/10.62347/ZKIG9938","url":null,"abstract":"<p><p>Primary liver cancer (PLC) often presents with subtle early symptoms, leading to most diagnoses at advanced stages, which negatively impacts treatment outcomes. This study evaluated the efficacy and safety of albumin-bound paclitaxel (nab-PTX) combined with Oxaliplatin (OXA) in the treatment of advanced PLC patients without surgical indications. A total of 126 patients with advanced PLC were divided into two treatment groups: the nab-PTX/OXA group (n=66) and the sorafenib (Sor)/OXA group (n=60), with a treatment cycle of 21 days. Clinical response rates, sleep quality (SQ), quality of life (QoL), prognosis, and adverse reactions were compared between the two groups. The results indicated that, after treatment, the nab-PTX/OXA group demonstrated significantly higher objective response rate, sleep quality (PSQI score), and QoL (SF-36 score) compared to the Sor/OXA group (all <i>P</i><0.05). Both groups demonstrated significant increases in Cluster of Differentiation 3-positive (CD3+) and CD4+ cell levels at Day 21 compared to Day 0 (<i>P</i><0.05), with a greater increase observed in the nab-PTX/OXA group (<i>P</i><0.05). Conversely, CD8+ cell levels were significantly decreased at Day 21 compared to Day 0 in both groups (<i>P</i><0.05), with a more pronounced decrease in the nab-PTX/OXA group (<i>P</i><0.05). Additionally, the CD4+/CD8+ ratio was significantly elevated at Day 21 compared to Day 0 in both groups (<i>P</i><0.05), with a greater increase observed in the Sor/OXA group (<i>P</i><0.05). Furthermore, the overall survival (OS) and progression-free survival (PFS) in the nab-PTX/OXA group were significantly longer than those in the Sor/OXA group (<i>P</i><0.05). In the nab-PTX/OXA group, the incidence of abdominal pain and diarrhea, grade III-IV leukopenia, thrombocytopenia, and liver and kidney dysfunction was significantly lower than that in the Sor/OXA group (<i>P</i><0.05). In short, PTX combined with OXA demonstrated favorable efficacy in treating advanced PLC. This regimen not only improved SQ and QoL but also prolonged survival.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1122-1132"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of glymphatic system function in the managing Cancer and Living Meaningfully (CALM) intervention to improve chemotherapy-related cognitive impairment (CRCI) in breast cancer survivors.","authors":"Chen Gan, Ling Cheng, Senbang Yao, Longyu Hu, Xinyi Zheng, Meiwen Ling, Jian Xu, Mingjun Zhang, Huaidong Cheng","doi":"10.62347/YWYC9782","DOIUrl":"https://doi.org/10.62347/YWYC9782","url":null,"abstract":"<p><strong>Objective: </strong>This study employed the diffusion tensor image analysis along the perivascular space (DTI-ALPS) index to investigate the glymphatic system's involvement in Managing Cancer and Living Meaningfully (CALM) intervention to improve chemotherapy-related cognitive impairment (CRCI) in breast cancer survivors (BCs).</p><p><strong>Methods: </strong>68 BCs were randomly assigned to the CALM (34 patients) or care-as-usual (CAU) (34 patients) groups. The Mini-Mental State Examination (MMSE) and Prospective and Retrospective Memory Questionnaire (PRMQ) were calculated for all patients before and after the intervention. Imaging data were collected from the CALM group to analyze the DTI-ALPS index before and after the intervention.</p><p><strong>Results: </strong>The CALM group showed significant improvements than the CAU group in MMSE (F = 6.612; <i>P</i> = 0.012), retrospective memory (RM) (F = 5.154; <i>P</i> = 0.027), and prospective memory (PM) (F = 8.731; <i>P</i> = 0.004) scores after the intervention. A significantly increased in the DTI-ALPS index was observed following CALM intervention compared to baseline (<i>t</i> = -2.111; <i>P</i> = 0.042). The ∆DTI-ALPS index was correlated with both ΔMMSE (<i>P</i> = 0.027, <i>r</i> = 0.378) and ∆RM (<i>P</i> = 0.026, <i>r</i> = -0.381) scores.</p><p><strong>Conclusion: </strong>CALM intervention improved CRCI and glymphatic function in BCs,with observed correlations between these enhancements.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1148-1157"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143951874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"β-sitosterol suppresses fibroblast growth factor and epidermal growth factor receptors to induce apoptosis and inhibit migration in lung cancer: an in vitro study.","authors":"Shun-An Kan, Musarat Hussain, Chikondi Jassi, Wei-Wen Kuo, Chia-Hua Kuo, Pei-Ying Pai, Shu-Hui Lin, Yueh-Min Lin, Chih-Yang Huang, Shinn-Zong Lin","doi":"10.62347/NZCG1179","DOIUrl":"https://doi.org/10.62347/NZCG1179","url":null,"abstract":"<p><p>β-Sitosterol (BS), is a significant bioactive component of phytosterols found in plants, foods, and dietary supplements. Its nutritional benefits include lowering of cholesterol levels, boost immune system as well as reduce inflammation. Previous studies have demonstrated its significant anticancer effects across various human cancers. However, the specific mechanisms of action of BS in lung cancer remain unclear. This study aimed to investigate the mechanisms through which BS exerts its anticancer properties in human lung cancer cells, focusing on its anti-proliferative, apoptotic, cytotoxic, and anti-migratory effects. We conducted an in vitro study to assess the effects of BS on lung cancer cell lines A549 and H1975. We used a range of assays, including MTT, western blot, wound healing, transwell migration, immunofluorescence, TUNEL, and cell survival assays, to evaluate the impact of BS on cell proliferation, apoptosis, cytotoxicity, and migration. Our findings indicate that BS inhibits the proliferation of lung cancer cells in a time- and dose-dependent manner. It significantly promotes apoptosis and impairs both cancer cell migration and survival. Additionally, BS suppresses the expression of both fibroblast growth factor receptor-1 (FGFR1) and epidermal growth factor (EGFR), leading to the downregulation of the PI3K/AKT/mTOR/CD1 signaling pathway. BS demonstrates significant anticancer potential in lung cancer cells by inhibiting proliferation, inducing apoptosis, and reducing cell migration. These effects are likely mediated by the concurrent downregulation of FGFR1 and EGFR, leading to the inhibition of the PI3K/AKT/mTOR/CD1 signaling pathway, thereby warranting further investigation of BS as a potential therapeutic agent for lung cancer.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1109-1121"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global, regional, and national burden of premenopausal and postmenopausal malignant melanoma from 1990 to 2021: a comprehensive cross-sectional analysis.","authors":"Xingchen Liu, Chengling Liu, Jiayu Li, Yanfang Liu, Liqiang Hao, Meng Guo, Jianming Zheng","doi":"10.62347/QBVC1497","DOIUrl":"https://doi.org/10.62347/QBVC1497","url":null,"abstract":"<p><p>Malignant melanoma is a highly fatal disease closely associated with sex hormones. This study aimed to evaluate the global burden and trends of malignant melanoma based on menopausal status. Data on the prevalence, disability-adjusted life years (DALYs), and mortality of malignant melanoma were obtained from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021. Age 55 was used as a threshold for menopausal status to assess global, regional, and national trends in disease burden among women. In 2021, the age-standardized prevalence rate (ASPR) of malignant melanoma was higher in women than men under 55 years but lower in women over 55 years. From 1990 to 2021, the ASPR for premenopausal women increased from 14.23 [95% uncertainty interval (UI) (13.79-14.60)] to 16.53 [95% UI (15.09-17.78)], while the age-standardized DALYs rate (ASDR) decreased from 14.04 [95% UI (12.20-15.61)] to 11.83 [95% UI (9.20-14.35)], and the age-standardized mortality rate (ASMR) decreased from 0.27 [95% UI (0.24-0.30)] to 0.23 [95% UI (0.18-0.28)]. For postmenopausal women, the ASPR increased from 55.01 [95% UI (51.71-57.23)] to 81.43 [95% UI (74.33-87.03)], while the ASDR decreased from 63.88 [95% UI (58.39-69.64)] to 56.11 [95% UI (48.79-63.66)], and the ASMR decreased from 2.96 [95% UI (2.69-3.19)] to 2.73 [95% UI (2.36-3.07)]. The disease burden was highest in high socio-demographic index (SDI) regions but has recently decreased, whereas a gradual increase was observed in high-middle SDI regions. At the national level, New Zealand had the highest ASPR for both premenopausal and postmenopausal women, with values of 245.63 [95% UI (209.56, 279.91)] and 909.37 [95% UI (754.63, 1037.39)], respectively. Regional variations in population-level determinants of disease burden were identified. The risk and prognosis of malignant melanoma in women may differ by menopausal status due to the interplay of sex hormones and the immune system. Further research is needed to develop tailored screening and treatment strategies for women across diverse SDI regions and menopausal statuses.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"15 3","pages":"1002-1019"},"PeriodicalIF":3.6,"publicationDate":"2025-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982713/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143958655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}